Soligenix Inc.

SNGX Healthcare Biotechnology

Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%
Market cap
$7.7M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−38.90
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(165.10%) (235.50%) (326.88%) (241.65%)
ROA
(102.63%) (121.75%) (149.35%) (125.95%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(149.62%) (214.80%) (370.87%) (157.37%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(2.25) (1.98) (1.06) (0.61)
Free Cash Flow
(9.76) (10.27) (10.78) (9.74)
Capital Expenditures
0.00 (0.01) — —
Other line items
Cash ROIC
(53.84%) (77.66%) (118.18%) (59.20%)
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Operating CF/Net income
0.87 0.93 0.98 0.95
Depreciation/Fixed assets
0.41 0.36 0.48 0.62
Capex/Depreciation
(1.22) (1.84) 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(2.25) (1.98) (1.06) (0.61)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 — —

Fold the line items

Columns are period end dates